Abstract

Targeting tumor-derived angiogenesis has emerged as a promising new treatment strategy in patients with glioblastoma. Cediranib (Recentin™) is a potent oral inhibitor of vascular endothelial growth factor (VEGF) receptors and has demonstrated improved progression-free survival in an uncontrolled phase II study of patients with recurrent glioblastoma. The drug is taken orally, once daily, and has a manageable side effect profile. In addition, it has potent anti-edema and steroid-sparing effects that might improve the quality of life of glioblastoma patients. Several clinical trials are ongoing testing cediranib in patients with gliomas.